NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning,
Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe PLC
(NASDAQ:GSM), AXT Inc (NASDAQ:AXTI), ChemoCentryx, Inc. (NASDAQ:CCXI), RedHill Biopharma Ltd. (NASDAQ:RDHL), GTx, Inc.
(NASDAQ:GTXI), and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), including updated fundamental summaries, consolidated fiscal
reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
GSM DOWNLOAD: http://Fundamental-Markets.com/register/?so=GSM
AXTI DOWNLOAD: http://Fundamental-Markets.com/register/?so=AXTI
CCXI DOWNLOAD: http://Fundamental-Markets.com/register/?so=CCXI
RDHL DOWNLOAD: http://Fundamental-Markets.com/register/?so=RDHL
GTXI DOWNLOAD: http://Fundamental-Markets.com/register/?so=GTXI
ACHN DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACHN
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine
Ferroglobe PLC (NASDAQ:GSM), AXT Inc (NASDAQ:AXTI), ChemoCentryx, Inc. (NASDAQ:CCXI), RedHill Biopharma Ltd. (NASDAQ:RDHL), GTx,
Inc. (NASDAQ:GTXI), and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on a fundamental level and outlines the overall demand for
their products and services in addition to an in-depth review of the business strategy, management discussion, and overall
direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone
summaries and as such, important information may be missing from these samples. Please download the entire research report, free of
charge, to ensure you are reading all relevant material information. All information in this release was accessed August 16th,
2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
FERROGLOBE PLC (GSM) REPORT OVERVIEW
Ferroglobe's Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Ferroglobe reported revenue of $560.70MM vs
$396.04MM (up 41.58%) and basic earnings per share $0.21 vs -$0.04. For the twelve months ended December 31st, 2017 vs December
31st, 2016, Ferroglobe reported revenue of $1,741.69MM vs $1,576.04MM (up 10.51%) and basic earnings per share -$0.00 vs -$1.97.
Ferroglobe is expected to report earnings on August 21st, 2018. The report will be for the fiscal period ending June 30th, 2018.
The reported EPS for the same quarter last year was $0.05. The estimated EPS forecast for the next fiscal year is $0.94 and is
expected to report on February 25th, 2019.
To read the full Ferroglobe PLC (GSM) report, download it here: http://Fundamental-Markets.com/register/?so=GSM
-----------------------------------------
AXT INC (AXTI) REPORT OVERVIEW
AXT's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, AXT reported revenue of $27.12MM vs $23.56MM (up
15.13%) and basic earnings per share $0.10 vs $0.05 (up 100.00%). For the twelve months ended December 31st, 2017 vs December 31st,
2016, AXT reported revenue of $98.67MM vs $81.35MM (up 21.30%) and basic earnings per share $0.27 vs $0.17 (up 58.82%). AXT is
expected to report earnings on October 24th, 2018. The report will be for the fiscal period ending September 30th, 2018. The
reported EPS for the same quarter last year was $0.11. The estimated EPS forecast for the next fiscal year is $0.51 and is expected
to report on February 20th, 2019.
To read the full AXT Inc (AXTI) report, download it here: http://Fundamental-Markets.com/register/?so=AXTI
-----------------------------------------
CHEMOCENTRYX, INC. (CCXI) REPORT OVERVIEW
ChemoCentryx's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, ChemoCentryx reported revenue of $15.02MM vs
$8.94MM (up 68.09%) and basic earnings per share -$0.14 vs -$0.19. For the twelve months ended December 31st, 2017 vs December
31st, 2016, ChemoCentryx reported revenue of $82.50MM vs $11.94MM (up 591.22%) and basic earnings per share $0.37 vs -$0.86.
ChemoCentryx is expected to report earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th,
2018. The reported EPS for the same quarter last year was -$0.13. The estimated EPS forecast for the next fiscal year is -$1.29 and
is expected to report on March 8th, 2019.
To read the full ChemoCentryx, Inc. (CCXI) report, download it here: http://Fundamental-Markets.com/register/?so=CCXI
-----------------------------------------
REDHILL BIOPHARMA LTD. (RDHL) REPORT OVERVIEW
RedHill Biopharma's Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, RedHill Biopharma reported revenue of
$4.01MM vs $0.10MM (up 3,867.33%) and basic earnings per share -$2.58 vs -$2.29. RedHill Biopharma is expected to report earnings
on August 21st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last
year was -$0.60. The estimated EPS forecast for the next fiscal year is -$1.48 and is expected to report on February 28th,
2019.
To read the full RedHill Biopharma Ltd. (RDHL) report, download it here: http://Fundamental-Markets.com/register/?so=RDHL
-----------------------------------------
GTX, INC. (GTXI) REPORT OVERVIEW
GTx's Recent Financial Performance
GTx is expected to report earnings on November 13th, 2018. The report will be for the fiscal period ending
September 30th, 2018. The reported EPS for the same quarter last year was -$0.53. The estimated EPS forecast for the next fiscal
year is -$1.81 and is expected to report on March 11th, 2019.
To read the full GTx, Inc. (GTXI) report, download it here: http://Fundamental-Markets.com/register/?so=GTXI
-----------------------------------------
ACHILLION PHARMACEUTICALS, INC. (ACHN) REPORT OVERVIEW
Achillion Pharmaceuticals' Recent Financial Performance
Achillion Pharmaceuticals is expected to report earnings on November 7th, 2018. The report will be for the
fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast
for the next fiscal year is -$0.61 and is expected to report on February 28th, 2019.
To read the full Achillion Pharmaceuticals, Inc. (ACHN) report, download it here: http://Fundamental-Markets.com/register/?so=ACHN
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading
brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals
worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA®
BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst®
(CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes
qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers.
Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit
firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries
regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail
at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental
Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result
from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the
material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the
publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm,
investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full
disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network
manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority,
Inc.
